Molecular radiotherapy developer Theragnostics said it has signed an intellectual property agreement with AstraZeneca.
The agreement allows Theragnostics to develop radiotherapy based on radionuclide-labeled poly (ADP-ribose) polymerase (PARP) inhibitors, a class of oncology drugs that block the PARP enzyme, which cancer cells use in response to DNA damage.Theragnostics inks AstraZeneca agreement
Latest in Radiation Oncology/Therapy
GT Medical releases interim data for GammaTile trial
October 21, 2025
Pluvicto reduces progression of advanced prostate cancer
October 20, 2025
Accuray taps new CEO
October 20, 2025
Could more imaging access improve prison cancer care?
October 15, 2025



















